The company will use the offering to help finance the $4.5 billion acquisition of Omega Pharma.
OTC pharmaceutical company Perrigo Company (NYSE:PRGO; TASE:PRGO) has filed a prospectus with the US Securities and Exchange Commission (SEC) to raise $900 million in a secondary offering on Wall Street. The funds will be used to help acquire Belgian OTC manufacturer Omega Pharma for $4.5 billion, which Perrigo announced earlier this month.
Perrigo's NYSE offering could rise above $1 billion if joint book-running managers J.P. Morgan, Barclays and Bank of America Merrill Lynch agree to buy options.
At the current price of Perrigo's share, the offering represents a 4.5% stake in the company. Perrigo had cash reserves of $862 million at the end of the last quarter. The company, managed by President and CEO Joseph Papa, has a market cap of $21.3 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on November 20, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014
Joseph Papa